Latest Period
Q1 2026
Security Snapshot
LENZ Therapeutics, Inc. - Common Stock (LENZ) Institutional Ownership
CUSIP: 52635N103
13F Institutional Holders and Ownership History from Q1 2024 to Q1 2026
Institutions Reporting
143
Shares (Excl. Options)
33,125,366
Price
$9.15
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- LENZ on Nasdaq
- Shares outstanding
- 31,105,155
- Price per share
- $9.05
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 33,125,366
- Total reported value
- $303,087,053
- % of total 13F portfolios
- 0%
- Share change
- -2,000,664
- Value change
- -$46,524,977
- Number of holders
- 143
- Price from insider filings
- $9.05
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- LENZ - LENZ Therapeutics, Inc. - Common Stock is tracked under CUSIP 52635N103.
- 143 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 161 to 143 between Q4 2025 and Q1 2026.
- Reported value moved from $561,546,547 to $303,087,053.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 143 institutions filings for Q1 2026.
Security key
52635N103
Latest holder period
Q1 2026
13F holders
143
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
LENZ full holder history
LENZ Therapeutics, Inc. SEC filings
LENZ Therapeutics, Inc. company facts
LENZ Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 52635N103:
Significant Owners of LENZ Therapeutics, Inc. - Common Stock (LENZ) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 14% | -10% | $198,668,637 | +$209,610 | 4,265,106 | +0.11% | RA Capital Management, L.P. | 05 Nov 2025 |
| FMR LLC | 12% | -21% | $59,243,480 | -$9,208,416 | 3,702,718 | -13% | FMR LLC | 31 Dec 2025 |
| BlackRock, Inc. | 5.8% | +18% | $16,515,263 | +$2,438,486 | 1,804,099 | +17% | BlackRock, Inc. | 31 Mar 2026 |
| Squarepoint Ops LLC | 5.1% | $14,897,009 | 1,593,246 | Squarepoint Ops LLC | 01 Apr 2026 | |||
| Point72 Asset Management, L.P. | 4.8% | $63,244,042 | 1,357,751 | Steven A. Cohen | 30 Sep 2025 | |||
| Paradigm Biocapital Advisors LP | 3.8% | -28% | $50,001,813 | -$16,133,961 | 1,073,461 | -24% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| Versant Venture Capital VI, L.P. | 3.4% | -18% | $48,936,901 | -$6,192,532 | 1,050,599 | -11% | Versant Venture Capital VI, L.P. | 05 Nov 2025 |
As of 31 Mar 2026, 143 institutional investors reported holding 33,125,366 shares of LENZ Therapeutics, Inc. - Common Stock (LENZ). This represents 106% of the company’s total 31,105,155 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of LENZ Therapeutics, Inc. - Common Stock (LENZ) together control 93% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 13% | 4,178,823 | 0% | 0.41% | $38,236,230 |
| Alpha Wave Global, LP | 12% | 3,612,211 | 0% | 4.2% | $33,051,731 |
| FMR LLC | 12% | 3,597,784 | -2.8% | 0% | $32,919,721 |
| Versant Venture Management, LLC | 8.5% | 2,656,888 | 0% | 17% | $24,310,525 |
| BlackRock, Inc. | 6.4% | 1,976,823 | +17% | 0% | $18,087,931 |
| Squarepoint Ops LLC | 4.8% | 1,506,499 | +206% | 0.03% | $13,784,466 |
| Aberdeen Group plc | 3.7% | 1,156,161 | +136% | 0.02% | $10,578,873 |
| FRANKLIN RESOURCES INC | 3.5% | 1,100,148 | +0.35% | 0% | $10,066,354 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 1,041,188 | 0% | 0% | $9,526,870 |
| 72 Investment Holdings, LLC | 3.3% | 1,017,751 | 0% | 19% | $9,312,422 |
| MILLENNIUM MANAGEMENT LLC | 2.8% | 869,257 | +61% | 0.01% | $7,953,702 |
| C WorldWide Group Holding A/S | 2.3% | 700,000 | +40% | 0.14% | $6,405,000 |
| MORGAN STANLEY | 2.1% | 648,848 | +178% | 0% | $5,936,959 |
| BANK OF AMERICA CORP /DE/ | 1.8% | 547,534 | +377% | 0% | $5,009,937 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 524,574 | +14% | 0% | $4,800,891 |
| Blue Owl Capital Holdings LP | 1.6% | 506,722 | +238% | 1.2% | $4,636,506 |
| TWO SIGMA INVESTMENTS, LP | 1.6% | 500,997 | +71% | 0% | $4,584,123 |
| PRIMECAP MANAGEMENT CO/CA/ | 1.5% | 472,200 | +27% | 0% | $4,320,630 |
| Alyeska Investment Group, L.P. | 1.5% | 463,495 | 0% | 0.01% | $4,240,979 |
| TANG CAPITAL MANAGEMENT LLC | 1.5% | 451,114 | -48% | 0.21% | $4,127,696 |
| STATE STREET CORP | 1.3% | 402,225 | -21% | 0% | $3,680,359 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 0.91% | 283,206 | +62% | 0.02% | $2,591,335 |
| Rock Springs Capital Management LP | 0.83% | 257,460 | 0% | 0.14% | $2,355,759 |
| DISCOVERY CAPITAL MANAGEMENT, LLC / CT | 0.78% | 241,300 | 0% | 0.11% | $2,207,895 |
| XTX Topco Ltd | 0.71% | 221,037 | +158% | 0.04% | $2,022,489 |
Institutional Holders of LENZ Therapeutics, Inc. - Common Stock (LENZ) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 33,125,366 | $303,087,053 | -$46,524,977 | $9.15 | 143 |
| 2025 Q4 | 35,070,612 | $561,546,547 | -$86,155,656 | $16.00 | 161 |
| 2025 Q3 | 29,140,610 | $1,355,578,952 | +$224,909,861 | $46.58 | 166 |
| 2025 Q2 | 24,727,156 | $725,109,733 | +$107,969,187 | $29.31 | 113 |
| 2025 Q1 | 21,072,237 | $541,761,121 | +$29,092,976 | $25.71 | 105 |
| 2024 Q4 | 19,863,850 | $573,239,116 | +$35,341,897 | $28.87 | 94 |
| 2024 Q3 | 18,735,645 | $444,795,067 | -$1,423,016 | $23.74 | 78 |
| 2024 Q2 | 18,913,542 | $327,016,869 | +$45,118,057 | $17.29 | 63 |
| 2024 Q1 | 16,171,755 | $361,085,230 | +$360,723,016 | $22.33 | 54 |